Biogen Inc. (BIIB) Earnings Call Transcripts
Biogen Inc.'s Latest Earnings Call - Q3 FY2026
In the third quarter of 2026, Biogen Inc. reported total revenue of $2.8 billion, reflecting an 11% year-over-year growth, driven significantly by the acquisition of Apellis. The company achieved a core pharmaceutical revenue of $2 billion, up 18% year-over-year, with notable contributions from its growth portfolio, which generated approximately $1.3 billion, marking a 49% increase. Management raised the lower end of its non-GAAP diluted EPS guidance for the full year 2026 to between $12.20 and $13, indicating confidence in sustained growth and improved operational efficiency following the Apellis integration.
Reported metrics
| Metric | Value |
|---|---|
| Total Revenue | $2.8 billion (positive) |
| Core Pharmaceutical Revenue | $2 billion (positive) |
| SPINRAZA Revenue | $461 million (positive) |
| SYFOVRE Revenue | $191 million (positive) |
| Free Cash Flow | $600 million |
| Non-GAAP Diluted EPS Guidance | $12.20 - $13 (positive) |
Guidance from management
Biogen is on track to deliver top-line growth for the first time in several years and has raised its non-GAAP diluted EPS guidance for 2026 to between $12.20 and $13, reflecting confidence in operational improvements and synergy capture from the Apellis acquisition.
What management said
Apologies, and thank you, Phil. So, taking a step back, we do recognize and acknowledge that lupus is a highly heterogeneous disease. We’ve examined previous trials — and we have extensively implemented multiple strategies in order to optimize the outcomes. I’ve talked about those before; and just to name a few. The steroid tapering, control of background standard of care meds. So there isn’t really anything new that...
Thank you, Brian. Taking a step back, my view is that interferon gene signature is something we expect to be high among SLE patients generally, and the literature backs that up as well. And truly, looking at baseline, we aren't aware of any differences between LiLAC and TOPAZ-1 and 2 when it comes to interferon gene signature. We will only find out later, once we examine the data, and these are areas we will be looki...
What analysts pressed on
Analysts expressed concerns regarding the potential drop in revenue from Q3 to Q4, questioning the sustainability of the growth trajectory. There were also inquiries about the competitive landscape for new product launches and the effectiveness of market education efforts for SYFOVRE and EMPAVELI.
Main topics on the call
- Strong Revenue Growth — Biogen achieved total revenue of $2.8 billion in Q3 2026, which is an 11% increase year-over-year. Management highlighted that this growth was significantly aided by the Apellis acquisition, stating, "the integration has...
- Growth Portfolio Performance — The growth portfolio generated approximately $1.3 billion in revenue, up 49% year-over-year, representing about 63% of total core pharmaceutical revenue. Management noted, "the growth portfolio has now exceeded the legac...
- Guidance Update — Biogen raised the lower end of its non-GAAP diluted EPS guidance for 2026 to between $12.20 and $13, reflecting confidence in operational improvements and synergy capture from the Apellis acquisition. Robin Kramer stated...
- Pipeline Developments — Management emphasized the strength of their late-stage pipeline, with multiple registrational readouts expected in the coming months. Priya Singhal mentioned, "we expect to continue our multiyear cycle of important regis...
Read the full Biogen Inc. transcript (Q3 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Biogen Inc.
Biogen Inc. (BIIB) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NASDAQ and is based in US. EarningsCalls.dev maintains a full-text archive of its earnings call transcripts — 28 calls on record spanning January 30, 2020 to October 28, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics. The latest calls are free to read; the full history is available through our REST API.
Earnings Call History
EarningsCalls.dev has 28 Biogen Inc. earnings call transcripts on record, spanning January 30, 2020 to October 28, 2026. Based on this history, Biogen Inc. reports quarterly. The most recent call on file is dated October 28, 2026. The full list is below — each row opens the transcript.
- Ticker
- BIIB
- Exchange
- NASDAQ
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 28
- First call
- January 30, 2020
- Most recent
- October 28, 2026
- Reporting cadence
- quarterly